Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.
Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Barr KJ, Liu G, Gehrke L, Credo RB, Hui YH, Lee J, Warner RB, Kovar P, Nukkala MA, Zielinski NA, Tahir SK, Fitzgerald M, Kim KH, Marsh K, Frost D, Ng SC, Rosenberg S, Sham HL. Li Q, et al. Among authors: barr kj. Bioorg Med Chem Lett. 2002 Feb 11;12(3):465-9. doi: 10.1016/s0960-894x(01)00759-4. Bioorg Med Chem Lett. 2002. PMID: 11814821
Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.
Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH, Sham HL. Wang L, et al. Among authors: barr kj. J Med Chem. 2002 Apr 11;45(8):1697-711. doi: 10.1021/jm010523x. J Med Chem. 2002. PMID: 11931625
Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.
O'Connor SJ, Barr KJ, Wang L, Sorensen BK, Tasker AS, Sham H, Ng SC, Cohen J, Devine E, Cherian S, Saeed B, Zhang H, Lee JY, Warner R, Tahir S, Kovar P, Ewing P, Alder J, Mitten M, Leal J, Marsh K, Bauch J, Hoffman DJ, Sebti SM, Rosenberg SH. O'Connor SJ, et al. Among authors: barr kj. J Med Chem. 1999 Sep 9;42(18):3701-10. doi: 10.1021/jm9901935. J Med Chem. 1999. PMID: 10479301
Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.
Gwaltney SL 2nd, Imade HM, Barr KJ, Li Q, Gehrke L, Credo RB, Warner RB, Lee JY, Kovar P, Wang J, Nukkala MA, Zielinski NA, Frost D, Ng SC, Sham HL. Gwaltney SL 2nd, et al. Among authors: barr kj. Bioorg Med Chem Lett. 2001 Apr 9;11(7):871-4. doi: 10.1016/s0960-894x(01)00098-1. Bioorg Med Chem Lett. 2001. PMID: 11294380
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV, Hanan EJ, Romanowski MJ, Elling RA, Lew W, Barr KJ, Zhu J, Yoburn JC, Liu Y, Fahr BT, Fan J, Lu Y, Pham P, Choong IC, VanderPorten EC, Bui M, Purkey HE, Evanchik MJ, Yang W. Fucini RV, et al. Among authors: barr kj. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5648-52. doi: 10.1016/j.bmcl.2008.08.095. Epub 2008 Aug 29. Bioorg Med Chem Lett. 2008. PMID: 18793847
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM. Zhong M, et al. Among authors: barr kj. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23. Bioorg Med Chem Lett. 2010. PMID: 20655213
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Lin J, Lu W, Caravella JA, Campbell AM, Diebold RB, Ericsson A, Fritzen E, Gustafson GR, Lancia DR Jr, Shelekhin T, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Diep H, Kershaw M, Yao L, Kauffman G, Hubbs SE, Luke GP, Toms AV, Wang L, Bair KW, Barr KJ, Dinsmore C, Walker D, Ashwell S. Lin J, et al. Among authors: barr kj. J Med Chem. 2019 Jul 25;62(14):6575-6596. doi: 10.1021/acs.jmedchem.9b00362. Epub 2019 Jul 8. J Med Chem. 2019. PMID: 31199148
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Kershaw M, Yao L, Toms AV, Barr KJ, Dinsmore CJ, Walker D, Ashwell S, Lu W. Caravella JA, et al. Among authors: barr kj. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. J Med Chem. 2020. PMID: 31971798
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.
Zhong M, Hanan EJ, Shen W, Bui M, Arkin MR, Barr KJ, Evanchik MJ, Hoch U, Hyde J, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM. Zhong M, et al. Among authors: barr kj. Bioorg Med Chem Lett. 2011 Jan 1;21(1):307-10. doi: 10.1016/j.bmcl.2010.11.014. Epub 2010 Nov 5. Bioorg Med Chem Lett. 2011. PMID: 21109434
Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme.
Elling RA, Fucini RV, Hanan EJ, Barr KJ, Zhu J, Paulvannan K, Yang W, Romanowski MJ. Elling RA, et al. Among authors: barr kj. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Aug 1;64(Pt 8):686-91. doi: 10.1107/S1744309108019623. Epub 2008 Jul 26. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008. PMID: 18678933 Free PMC article.
52 results